To evaluate the safety and efficacy of saroglitazar among pre-diabetes and dyslipidemia
Keywords:
saroglitazar, prediabetes, dyslipidemiaAbstract
Patients with prediabetes are not only at increased risk of progression to type 2 diabetes, but they are also at high risk of developing cardiovascular (CV) risk compared to normoglycemic people. Further, prediabetes is also often associated with abnormal lipid levels (dyslipidemia). We therefore aimed to evaluate the effect of saroglitazar in patients with prediabetes and dyslipidemia. This was a prospective, single centre, single arm study involving patients with pre-diabetes and dyslipidemia. Subjects with baseline HbA1c 5.7-6.4% and dyslipidemia were enrolled in this study. Subjects with on-going medications affecting blood glucose or lipids were excluded from the study. Saroglitazar 4mg once daily was administered for a period of 24 weeks. The primary outcome was change in serum triglycerides and secondary outcome parameters included changes in other lipid parameters and HbA1c levels at 24 weeks follow-up. Forty patients with prediabetes and dyslipidemia were enrolled in the study. At 24 weeks follow-up, serum triglycerides was significantly reduced from 348 mg/dl to 216 mg/dl (P <0.0001). HbA1c was significantly reduced from 6.3% to 5.5% after 24 weeks of Saroglitazar therapy (P<0.0001).
Downloads
References
International Diabetes Federation. IDF Diabetes Atlas, 7 ed. Brussels, Belgium: International Diabetes Federation, 2015.
Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R et al., Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003; 26: 3160–3167.
Larson H, Lindgarde F, Berglund G, Ahren B. Prediction of diabetes using ADA or WHO criteria in post-menopausal women: a 10-year follow-up study. Diabetologia.2004; 43: 1224–1228.
Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol. 2010; 55: 1310–1317.
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA.et al., Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement (erratum in: Circulation 2005;112:e297–8). Circulation 2005;112:2735–2752.
Reaven GM. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. Panminerva Med. 2005; 47:201–210.
Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program–Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care. 2007;30: 8 –13.
Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care.2004;27:2676–2681.
Pai V, Paneerselvam A, Mukhopadhyay S, Bhansali A, Kamath D, Shankar V. et al., A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V). Journal of Diabetes Science and Technology. 2014;8(1):132-141.
Jani R, Pai V, Jha P, Jariwala G, Mukhopadhyay S, Bhansali A. et al., A Multicenter, Prospective, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared with Placebo in Type 2 Diabetes Mellitus Patients Having Hypertriglyceridemia Not Controlled with Atorvastatin Therapy (PRESS VI). Diabetes Technology & Therapeutics. 2014;16(2):63-71.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106: 3143–3421.
Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di AE. et al., Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010; 375:2215–2222.
Earl S Ford, Chaoyang Li , Sniderman A : Temporal changes in concentrations of lipids and apolipoprotein B among adults with diagnosed and undiagnosed diabetes, prediabetes, and normoglycemia: findings from the National Health and Nutrition Examination Survey 1988–1991 to 2005–2008. Cardiovascular Diabetology. 2013; 12:26
Unnikrishnan R, Anjana RM., and Mohan V. Diabetes in South Asians: Is the Phenotype Different? Diabetes. 2014; 63:53–55.
Anjana RM, Pradeepa R, Deepa M, Datta M, Sudha V, Unnikrishnan R.et al., ICMR–INDIAB Collaborative Study Group. Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: phase I results of the Indian Council of Medical Research-INdia DIABetes (ICMR-INDIAB) study. Diabetologia. 2011;54: 3022–3027
Ramachandran A, Snehalatha C, Viswanathan V, Viswanathan M, Haffner SM. Risk of noninsulin dependent diabetes mellitus conferred by obesity and central adiposity in different ethnic groups: a comparative analysis between Asian Indians, Mexican Americans and Whites. Diabetes Res Clin Pract. 1997;36: 121–125
Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009 ;5:150-159.
Inzucchi S, Amatruda J. Lipid management in patients with diabetes: translating guidelines into action. Diabetes Care. 2003; 26:1309-1311.
Murad MH, Hazem A, Coto-Yglesias F, Dzyubak S, Gupta S, Bancos I.et al., The association of hypertriglyceridemia with cardiovascular events and pancreatitis: a systematic review and meta-analysis.BMC Endocr Disord. 2012;12:2
Leiter LA, Lundman P, da Silva PM. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study.Diabet Med. 2011;28:1343-51
Feher M, Greener M, Munro N. Persistent hypertriglyceridemia in statin treated patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2013;6:11-15
Berg Jørgensen A, Frikke-Schmidt R, Børge G. Nordestgaard, and Tybjærg-Hansen A. Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease. N Engl J Med. 2014; 371:32-41
Shetty SR , Kumar S , Mathur RP , Sharma KH , Jaiswal AD.Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients. Indian Heart J .2015; 67: 23-26.
Inzucchi SE, Viscoli CM, Young LH, Furie KL, Gorman M, Lovejoy AM. Pioglitazone Prevents Diabetes in Insulin-Resistant Patients With Cerebrovascular Disease. Diabetes Care .2016; 39:1684-1692.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
